Results 161 to 170 of about 140,144 (311)
Current role of colony stimulating factors in the management of neutropenia
Colony stimulating factors are naturally occurring proteins that promote the growth. Synthesized versions exist that bind the same receptors, often acting in the same ways as their organic counterparts.
Al-kharouf, Issa
core
The combination of immune checkpoint inhibitors (ICIs) and radiotherapy synergistically enhances efficacy through an “antigen release‐immune activation” closed‐loop mechanism, significantly improving outcomes in solid tumors (e.g., lung cancer, melanoma).
Guiling Song +5 more
wiley +1 more source
Incidence of Clinically Significant Neutropenia and Complications Related to Antibody-Drug Conjugates: A Real-World Study at the University of California. [PDF]
Jan T +4 more
europepmc +1 more source
There is no specific therapeutic drug regimen for radiation esophagitis. In previous studies, radiation esophagitis was considered a self‐limiting disease; however, current clinical approaches are limited to symptomatic treatment, which yields unsatisfactory therapeutic outcomes.
Hao Zhang +7 more
wiley +1 more source
Risk Factors and Clinical Significance of Grade ≥3 Neutropenia During the First Cycle of Cabazitaxel Therapy With Primary Pegfilgrastim Prophylaxis in Metastatic Castration-resistant Prostate Cancer. [PDF]
Sato R +4 more
europepmc +1 more source
ABSTRACT Background As overall survival improves in metastatic hormone‐sensitive prostate cancer (mHSPC), non‐cancer causes of death are increasingly relevant. Methods We conducted a real‐world multicenter study of patients diagnosed with mHSPC treated with ADT alone or in combination. Causes of death before progression to castration‐resistant prostate
Marta Garcia de Herreros +15 more
wiley +1 more source
Exposure-safety analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial. [PDF]
Wang Y +9 more
europepmc +1 more source
Abstract Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease‐induced and treatment‐related cytopenias.
Neha Thakre +5 more
wiley +1 more source
Risk factors associated with blood dyscrasia during clozapine treatment: a systematic review and meta-analysis. [PDF]
Casetta C +4 more
europepmc +1 more source
Graphical abstract summarizing the multifactorial pathogenesis of rheumatoid arthritis (RA) and the therapeutic potential of mesenchymal stromal cell (MSC) therapy. MSCs provide promising benefits through their immunomodulatory properties, low immunogenicity, ability to promote tissue repair, and multi‐lineage differentiation, presenting a potential ...
Yingjia Chen +6 more
wiley +1 more source

